Kangxinu: Reconstructed trivalent poliomyelitis vaccine obtains approval notice for clinical trial of medicine.

Kexing announcement, recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on the recombinant trivalent polio vaccine. The vaccine is prepared through protein structure design and VLP assembly technology, and is expected to have good safety and immunogenicity. Currently, the vaccine is undergoing Phase I/II clinical trials in Indonesia. The recombinant polio vaccine meets the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of polio caused by type I, II, and III viruses.